Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Prior treatment

• Active solid malignancy or haematological malignancies including chronic lymphocytic leukaemia, (unless indolent or non-life-threatening) within the last 5 years. For clarity, exceptions include other non-melanoma skin cancer that has undergone potentially curative therapy, or in-situ cervical carcinoma or in-situ prostate cancer with non-detectable prostate specific antigen or any other tumour that has been treated, and the patient is deemed to be in complete remission for at least 2 years prior to enrolment.
• Steroid use \>10mg prednisone per day within 14 days of study drug (except if physiologic replacement).
• Receipt of live vaccine (including attenuated) within 30 days of first study treatment.
• Prior transplant recipient (corneal transplant patients are eligible).
• Prior PD-L1/PD-1 inhibitor exposure for the same lesion as enrolment.
• Any anticancer treatment other than radiation therapy (such as chemotherapy, targeted systemic therapy, imiquimod, photodynamic therapy), either investigational or standard of care, within 30 days of the initial administration of cemiplimab or planned to occur during the study period.

Other illness

• Metastatic disease.
• Active autoimmune disease requiring active systemic therapy within the last 5 years.
• Interstitial lung disease or pneumonitis requiring systemic therapy in the last 5 years.
• History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments.
• Patients with allergy or hypersensitivity to cemiplimab or to any of the excipients must be excluded.

Lab values

• Active infection requiring therapy including human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV), or active tuberculosis.
• Breast-feeding or positive serum pregnancy test consistent with pregnancy (excluding false positives defined as a failure of βHCG doubling in 48 hours) or inability to comply with recommended contraception.

Other

• Squamous cell carcinoma of unknown primary (those with presumed clinical assessment of CSCC are eligible).
• Institutionalised patients by order of judicial or administrative authority.
• Not willing to comply with all study related procedures, particularly consent for collection of tumour and blood samples and imaging, at all protocol specified time points.

• Stage II to IV (M0) CSCC who are candidates for surgery, but who have an increased risk of recurrence and/or risk of disfigurement or loss of function. Patients with stage III or IV (M0) CSCC of the head/neck, extremity, or trunk are eligible, and patients with stage II CSCC (≥3 cm longest diameter in an aesthetically sensitive region).
• At least one measurable lesion per RECIST 1.1.
• Age ≥18 years.
• Histologically confirmed diagnosis of invasive CSCC.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
• Anticipated life expectancy \>12 weeks.
• Adequate organ function defined as:
  • Hepatic function:
  • Total bilirubin ≤1.5× upper limit of normal (ULN).
  • Patients with Gilbert's Disease and total bilirubin up to 3× ULN are eligible.
  • Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤3× ULN.
  • Alkaline phosphatase (ALP) ≤2.5× ULN. ii) Renal function: Serum creatinine ≤2× ULN or estimated creatinine clearance \>35 mL/min (according the method of Cockcroft and Gault). iii) Creatinine phosphokinase (CPK) (also known as CK \[creatinine kinase\]) elevation ≤ grade 2. iv) Bone marrow function:
  • <!-- -->
  • Haemoglobin ≥9.0 g/dL.
  • Absolute neutrophil count (ANC) ≥1.5 x 109/L.
  • Platelet count ≥75 x 109/L.